In diabetes management, cilostazol may enhance the peripheral circulation and insulin sensitivity, potentially augmenting the hypoglycemic effects of drugs like insulin or sulfonylureas, thereby increasing the risk of hypoglycemia [52,53]. Here, INS is linked to Hypoglycemia.